Adakveo (crizanlizumab): Phase III study (CSEG101A2301) shows no superiority of crizanlizumab over placebo

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Adakveo
Active substance
Crizanlizumab
Therapeutic area (MeSH)
Anemia, Sickle Cell
Procedure number
EMEA/H/C/004874
DHPC type
Referral - Article 20 procedure
Referral name
Adakveo
Human ATC code
B06AX01
Dissemination date
14/02/2023

How useful was this page?

Add your rating